Cardiol Therapeutics Inc. (CRDL) Institutional Ownership

Ownership Summary

Cardiol Therapeutics Inc. (NASDAQ:CRDL) is held by 40 institutional investors per 13F filings through December 2025.

• These investors held 10.7% of outstanding shares in December 2025, up from 9.3% in September 2025.
• They increased total shares held in Cardiol Therapeutics by 33.1% from the prior quarter, while the number of investors in CRDL decreased 9.09% year over year.
• Activity in CRDL broke down as 20 buyers, 11 sellers, and 9 unchanged among 40 total holders.
• Altogether, these fund groups held 9.09Mn shares in CRDL by December 2025, up by 2.26Mn shares quarter on quarter, and up 1.36Mn shares year over year.
• MMCAP International Inc. SPC is the top holder of Cardiol Therapeutics as of December 31, 2025, with 15.35Mn shares representing 18.12% of outstanding stock.
• Top purchasers of CRDL stock for the quarter ending December 2025 included MMCAP International Inc. SPC (15.14Mn), Ikarian Capital, LLC (2.72Mn), CITADEL ADVISORS LLC (819.9K), BOOTHBAY FUND MANAGEMENT, LLC (794.88K), RENAISSANCE TECHNOLOGIES LLC (229.81K).
• The largest sellers of Cardiol Therapeutics for the quarter ending December 2025 were Goldman Sachs Group Inc (324.6K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (133.33K), Morgan Stanley (94.04K), Boyer Financial Services, Inc. (10.0K), UBS Group AG (7.94K).
• Business Quant data shows the 10 biggest positions in Cardiol Therapeutics as of December 2025 are held by MMCAP International Inc. SPC (15.35Mn), Tejara Capital Ltd (5.13Mn), Ikarian Capital, LLC (2.72Mn), CITADEL ADVISORS LLC (819.9K), BOOTHBAY FUND MANAGEMENT, LLC (794.88K), TWO SIGMA INVESTMENTS, LP (534.21K), INTEGRITY ALLIANCE, LLC. (465.02K), Goldman Sachs Group Inc (332.4K), Morgan Stanley (250.42K), RENAISSANCE TECHNOLOGIES LLC (229.81K).